120 related articles for article (PubMed ID: 26735141)
1. An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.
Rizzieri DA; Cooley S; Odenike O; Moonan L; Chow KH; Jackson K; Wang X; Brail L; Borthakur G
Leuk Lymphoma; 2016 Aug; 57(8):1800-6. PubMed ID: 26735141
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
Gray JE; Infante JR; Brail LH; Simon GR; Cooksey JF; Jones SF; Farrington DL; Yeo A; Jackson KA; Chow KH; Zamek-Gliszczynski MJ; Burris HA
Invest New Drugs; 2015 Dec; 33(6):1187-96. PubMed ID: 26403509
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
Zamek-Gliszczynski MJ; Abraham TL; Alberts JJ; Kulanthaivel P; Jackson KA; Chow KH; McCann DJ; Hu H; Anderson S; Furr NA; Barbuch RJ; Cassidy KC
Drug Metab Dispos; 2013 Apr; 41(4):714-26. PubMed ID: 23305709
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.
Kunnimalaiyaan S; Schwartz VK; Jackson IA; Clark Gamblin T; Kunnimalaiyaan M
BMC Cancer; 2018 May; 18(1):560. PubMed ID: 29751783
[TBL] [Abstract][Full Text] [Related]
5. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Atkinson JM; Rank KB; Zeng Y; Capen A; Yadav V; Manro JR; Engler TA; Chedid M
PLoS One; 2015; 10(4):e0125028. PubMed ID: 25915038
[TBL] [Abstract][Full Text] [Related]
6. Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.
DiPersio JF; Erba HP; Larson RA; Luger SM; Tallman MS; Brill JM; Vuagniaux G; Rouits E; Sorensen JM; Zanna C
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):443-9. PubMed ID: 25842225
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
[TBL] [Abstract][Full Text] [Related]
9. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Perl AE; Kasner MT; Tsai DE; Vogl DT; Loren AW; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Frey NV; Nasta SD; Hexner EO; Dierov JK; Swider CR; Bagg A; Gewirtz AM; Carroll M; Luger SM
Clin Cancer Res; 2009 Nov; 15(21):6732-9. PubMed ID: 19843663
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.
Takeoka H; Yamada K; Azuma K; Zaizen Y; Yamashita F; Yoshida T; Naito Y; Okayama Y; Miyamoto M; Hoshino T
Jpn J Clin Oncol; 2014 May; 44(5):472-8. PubMed ID: 24688087
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
17. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
Müller-Tidow C; Bug G; Lübbert M; Krämer A; Krauter J; Valent P; Nachbaur D; Berdel WE; Ottmann OG; Fritsch H; Munzert G; Garin-Chesa P; Fleischer F; Taube T; Döhner H
Br J Haematol; 2013 Oct; 163(2):214-22. PubMed ID: 24033250
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
